Here's Why Everyone's So Excited About bluebird bio
Investors have seen bluebird bio's (NASDAQ: BLUE) share price skyrocket following impressive early-stage trial results for bb2121, a multiple myeloma gene therapy that's licensed to Celgene Corp. (NASDAQ: CELG). The excitement stems from a potential to leverage Celgene's dominant market position in multiple myeloma to turn bb2121 into a multibillion-dollar moneymaker. Here's how bluebird bio will benefit if that happens.
Celgene's been working with bluebird bio under a research collaboration since 2011, but it reworked its collaboration agreement in 2015 so that it includes bluebird bio's research on gene therapies that target BCMA, a protein commonly expressed on the surface of multiple myeloma cells.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Bluebird Bio Inc. Stock
Our community is currently low on Bluebird Bio Inc. with 4 Buy predictions and 6 Sell predictions.
On the other hand, the target price of 6 € is above the current price of 1.06 € for Bluebird Bio Inc., so the potential is actually 467.11%.
